AIFA
- Local brand name: Kesimpta
- Status: approved
Kesimpta (OFATUMUMAB) regulatory status in Italy.
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Yes. AIFA has authorised it.
Novartis is the originator. The local marketing authorisation holder may differ — check the official source linked above.